Evolution of the Biosimilars Landscape:Pfizer.
As a Pfizer staff member you are invited to attend this special biosimilars landscape webinar
By Giles Somers, Lead Analyst
I head up the Generics and Biosimilars team at Datamonitor Healthcare, where we aim to provide clients with concise stra...
Read full bio
Approval of the US biosimilar approval pathway has coincided with increased Big Pharma activity and a surge in new Phase III clinical trials. 2014 was a standout year for innovator biologic approvals, with more than 100 now authorized in the US. This largely untapped opportunity has now attracted a number of major pharmaceutical and generics companies. Competition for the most lucrative target molecules is high and only those participants with the right strategies will experience overall success. It’s crucial to understand the evolution of the market, company trends and also the long-term implications for you and your business.
Make sure you know what is happening across the global biosimilar market by joining Giles Somers on Tuesday 10th March at 3pm (GMT). He’ll talk you through the landscape for biosimilars and how it has evolved over the past five years and what the outlook is going forward.
In addition he will also talk through our new Autoimmune ExpiryView tool which will be launched soon, and release the findings of our recent biosimilars survey.
Key questions answered within this webinar:
- How competitive will the biosimilars market be?
- What do industry participants feel are the greatest challenges?
- Which are the next big reference products to go after?
- What does Datamonitor Healthcare’s Autoimmune ExpiryView tool do?